Table 3.
Comparison of laboratory analysis between women with a history of first trimester and second trimester pregnancy loss.
| Variables | First Trimester (n = 157) |
Second Trimester (n = 54) |
p-Value * |
|---|---|---|---|
| FVL heterozygous | 36 (22.9%) | 10 (18.5%) | 0.498 |
| FVL homozygous | 17 (10.8%) | 1 (1.9%) | 0.041 |
| PT heterozygous | 11 (7.0%) | 6 (11.1%) | 0.339 |
| FVL and PT (compound heterozygous) | 15 (9.6%) | 4 (7.4%) | 0.634 |
| Antithrombin deficiency | 13 (8.3%) | 4 (7.4%) | 0.838 |
| Protein C deficiency | 9 (5.7%) | 8 (14.8%) | 0.034 |
| Protein S deficiency | 14 (8.9%) | 6 (11.1%) | 0.634 |
| Free protein S deficiency | 7 (4.5%) | 5 (9.3%) | 0.188 |
| PAI-1 deficiency | 2 (1.3%) | 1 (1.9%) | 0.756 |
| ACE deletion | 9 (5.7%) | 3 (5.6%) | 0.961 |
| Factor VII deficiency | 16 (10.2%) | 4 (7.4%) | 0.546 |
| Factor XIII deficiency | 13 (8.3%) | 7 (13.0%) | 0.310 |
| β-fibrinogen polymorphism | 29 (18.5%) | 9 (16.7%) | 0.765 |
| Glycoprotein Ia polymorphism | 31 (19.7%) | 18 (33.3%) | 0.041 |
| tPA deficiency | 10 (6.4%) | 4 (7.4%) | 0.791 |
| APCR | 4 (2.5%) | 1 (1.9%) | 0.771 |
| APS antibodies ** | 28 (17.8%) | 3 (5.6%) | 0.027 |
| MTHFR gene mutation | 32 (20.4%) | 12 (22.2%) | 0.774 |
* Chi-square or Fisher’s exact test; ** Anticardiolipin antibodies IgG or IgM (ELISA), Anti-beta-2-glycoprotein-I antibodies IgG or IgM (ELISA), Lupus anticoagulants; PT—prothrombin; FVL—Factor V Leiden; MTHFR—Methylene tetrahydrofolate reductase; ACE—Angiotensin Converting Enzyme Deletion; APCR—Acquired activated protein C resistance; PAI-1—plasminogen activator inhibitor 1; tPA—plasminogen and tissue-type plasminogen activator deficiency; APS—antiphospholipid syndrome.